BioCorRx (BICX) Notes Payables (2016 - 2025)
BioCorRx (BICX) has disclosed Notes Payables for 16 consecutive years, with $1.2 million as the latest value for Q4 2025.
- Quarterly Notes Payables fell 8.97% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 8.97% year-over-year, with the annual reading at $1.2 million for FY2025, 8.97% down from the prior year.
- Notes Payables hit $1.2 million in Q4 2025 for BioCorRx, down from $1.5 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.5 million in Q3 2025 to a low of $21480.0 in Q1 2021.
- Historically, Notes Payables has averaged $669929.4 across 5 years, with a median of $383983.5 in 2023.
- Biggest five-year swings in Notes Payables: surged 3578.35% in 2021 and later crashed 62.33% in 2022.
- Year by year, Notes Payables stood at $790110.0 in 2021, then tumbled by 62.33% to $297602.0 in 2022, then skyrocketed by 103.88% to $606750.0 in 2023, then skyrocketed by 121.39% to $1.3 million in 2024, then fell by 8.97% to $1.2 million in 2025.
- Business Quant data shows Notes Payables for BICX at $1.2 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.